Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 15/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CCND3 | P30281 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 7/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28270065 | 0.74 | GRM4 (0.37) | — | |
| SCHEMBL1270888 | 0.71 | PIM1 (0.54) | CDK2KDM4EALDH1A1HPGDAURKB | |
| SCHEMBL2458765 | 0.70 | CHEK1 (0.67) | CHEK1CDK1CDK4CCNA2CCND1 | |
| SCHEMBL2458766 | 0.70 | CHEK1 (0.67) | CHEK1CDK1CDK4CCNA2CCND1 | |
| SCHEMBL28378989 | 0.68 | PARP1 (0.43) | KDM4EALDH1A1HPGD | |
| SCHEMBL9980485 | 0.68 | GRM4 (0.63) | — | |
| SCHEMBL352379 | 0.68 | GRM4 (0.39) | — | |
| SCHEMBL5508124 | 0.67 | CHEK1 (0.61) | CHEK1CDK1CDK4CCNA2CCND1 | |
| SCHEMBL5508123 | 0.67 | CHEK1 (0.61) | CHEK1CDK1CDK4CCNA2CCND1 | |
| SCHEMBL30027409 | 0.66 | PTPN1 (0.45) | KDM4EMEN1ALDH1A1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108503648-B | Styryl pyrazolopyrimidine compound, pharmaceutical composition, preparation method and application | 安徽医科大学 | 2020-04-14 | — | — | CN | claimed |
| CN-108503648-A | Styryl Pyrazolopyrimidines, pharmaceutical composition and preparation method and purposes | 安徽医科大学 | 2018-09-07 | — | — | CN | claimed |
| CN-108503648-B | Styryl pyrazolopyrimidine compound, pharmaceutical composition, preparation method and application | 安徽医科大学 | 2020-04-14 | — | — | CN | disclosed |
| CN-108503648-B | Styryl pyrazolopyrimidine compound, pharmaceutical composition, preparation method and application | 安徽医科大学 | 2020-04-14 | — | — | CN | disclosed |
| CN-108503648-B | Styryl pyrazolopyrimidine compound, pharmaceutical composition, preparation method and application | 安徽医科大学 | 2020-04-14 | — | — | CN | disclosed |
| CN-109206427-A | Aromatic heterocycle vinyl Pyrazolopyrimidines, pharmaceutical preparation and preparation method and application | 安徽医科大学 | 2019-01-15 | — | — | CN | disclosed |
| CN-108503648-A | Styryl Pyrazolopyrimidines, pharmaceutical composition and preparation method and purposes | 安徽医科大学 | 2018-09-07 | — | — | CN | disclosed |
| CN-108503648-A | Styryl Pyrazolopyrimidines, pharmaceutical composition and preparation method and purposes | 安徽医科大学 | 2018-09-07 | — | — | CN | disclosed |
| CN-108503648-A | Styryl Pyrazolopyrimidines, pharmaceutical composition and preparation method and purposes | 安徽医科大学 | 2018-09-07 | — | — | CN | disclosed |
| EP-2217602-B1 | 1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2018-08-29 | — | — | EP | disclosed |
| CN-105541849-B | The ketone derivatives of the dihydro-pyrazolo of 6 cycloalkyl 1,5 [3,4 d] pyrimidine 4 and its purposes as PDE9A inhibitor | 勃林格殷格翰国际有限公司 | 2018-03-23 | — | — | CN | disclosed |
| US-8648085-B2 | 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-20110015193-A1 | 1, 5-DIHYDRO-PYRAZOLO (3, 4-D) PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MUDULATORS FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| EP-2217602-A1 | 1, 5-DIHYDRO-PYRAZOLO (3, 4-D) PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS FOR THE TEATMENT OF CNS DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009068617-A1 | 1, 5-DIHYDRO-PYRAZOLO (3, 4-D) PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS FOR THE TEATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015193-A1 | 1, 5-DIHYDRO-PYRAZOLO (3, 4-D) PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MUDULATORS FOR THE TREATMENT OF CNS DISORDERS | PDE9A, PDE7A, PDE1C | CHEK1 2079/4885CDK1 1733/4885CDK4 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.